Xencor, Inc. (NASDAQ:XNCR) Director Richard J. Ranieri Sells 2,993 Shares

Xencor, Inc. (NASDAQ:XNCR) Director Richard J. Ranieri sold 2,993 shares of the company’s stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $9.22, for a total transaction of $27,595.46. Following the completion of the sale, the director now directly owns 19,183 shares of the company’s stock, valued at $176,867.26. The trade was a 13.50% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Xencor Price Performance

XNCR opened at $8.31 on Wednesday. Xencor, Inc. has a 52-week low of $7.16 and a 52-week high of $27.24. The company has a 50 day moving average of $9.07 and a two-hundred day moving average of $14.88. The company has a market cap of $591.42 million, a P/E ratio of -2.72 and a beta of 0.87. The company has a quick ratio of 5.89, a current ratio of 5.89 and a debt-to-equity ratio of 0.16.

Xencor (NASDAQ:XNCR) last posted its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.06). Xencor had a negative net margin of 181.17% and a negative return on equity of 31.94%. The business had revenue of $32.73 million for the quarter, compared to analyst estimates of $23.44 million. During the same quarter in the previous year, the firm posted ($1.11) EPS. The business’s revenue was up 104.6% compared to the same quarter last year. On average, analysts expect that Xencor, Inc. will post -3.68 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the stock. Barclays reduced their price objective on shares of Xencor from $22.00 to $6.00 and set an “underweight” rating for the company in a research report on Thursday, May 8th. William Blair started coverage on Xencor in a research report on Monday, April 21st. They set an “outperform” rating on the stock. Wells Fargo & Company lowered their price objective on shares of Xencor from $37.00 to $33.00 and set an “overweight” rating for the company in a research note on Friday, February 28th. Wedbush reaffirmed an “outperform” rating and issued a $31.00 target price on shares of Xencor in a research report on Wednesday, April 30th. Finally, Wall Street Zen cut Xencor from a “hold” rating to a “sell” rating in a report on Friday, March 14th. Two analysts have rated the stock with a sell rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $28.00.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the stock. RTW Investments LP raised its holdings in shares of Xencor by 317.9% during the 4th quarter. RTW Investments LP now owns 2,402,883 shares of the biopharmaceutical company’s stock valued at $55,218,000 after buying an additional 1,827,883 shares during the period. BVF Inc. IL grew its position in Xencor by 169.3% in the fourth quarter. BVF Inc. IL now owns 2,288,760 shares of the biopharmaceutical company’s stock valued at $52,596,000 after acquiring an additional 1,438,760 shares in the last quarter. Braidwell LP raised its stake in shares of Xencor by 169.0% during the first quarter. Braidwell LP now owns 1,655,690 shares of the biopharmaceutical company’s stock valued at $17,617,000 after purchasing an additional 1,040,159 shares during the period. Primecap Management Co. CA raised its stake in shares of Xencor by 8.6% during the first quarter. Primecap Management Co. CA now owns 9,761,012 shares of the biopharmaceutical company’s stock valued at $103,857,000 after purchasing an additional 776,580 shares during the period. Finally, Nuveen Asset Management LLC boosted its stake in shares of Xencor by 452.4% in the fourth quarter. Nuveen Asset Management LLC now owns 837,082 shares of the biopharmaceutical company’s stock valued at $19,236,000 after purchasing an additional 685,557 shares during the period.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.